Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
|
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
  • [31] A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer
    Murphy, Adrian G.
    Zahurak, Marianna
    Shah, Mirat
    Weekes, Colin D.
    Hansen, Aaron
    Siu, Lillian L.
    Spreafico, Anna
    LoConte, Noelle
    Anders, Nicole M.
    Miles, Tearra
    Rudek, Michelle A.
    Doyle, L. Austin
    Nelkin, Barry
    Maitra, Anirban
    Azad, Nilofer S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1178 - 1188
  • [32] A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Chien, Amy Jo
    Cockerill, Alyson
    Fancourt, Craig
    Schmidt, Emmett
    Moasser, Mark M.
    Rugo, Hope S.
    Melisko, Michelle E.
    Ko, Andrew H.
    Kelley, R. Katie
    Korn, W. Michael
    Esserman, Laura J.
    van't Veer, Laura
    Yau, Christina
    Wolf, Denise M.
    Munster, Pamela N.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 521 - 530
  • [33] Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
    Zhao, Yuan-Yuan
    Tian, Ying
    Zhang, Jing
    Xu, Fei
    Yang, Yun-Peng
    Huang, Yan
    Zhao, Hong-Yun
    Zhang, Jian-Wei
    Xue, Cong
    Lam, Michael H.
    Yan, Li
    Hu, Zhi-Huang
    Dinglin, Xiao-Xiao
    Zhang, Li
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1827 - 1837
  • [34] A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206
    Chorner, Paige M.
    Moorehead, Roger A.
    PLOS ONE, 2018, 13 (02):
  • [35] Pan-AKT inhibitor MK-2206 demonstrates anti-leukemic potential in MLL-rearranged BCP-ALL cell lines and primary samples
    Fischer, E.
    Richter, A.
    Sekora, A.
    Henze, L.
    Escobar, Murua H.
    Roolf, C.
    Junghanss, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 35 - 35
  • [36] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Ueno, Hideki
    Kondo, Shunsuke
    Yoshikawa, Shusuke
    Inoue, Koichi
    Andre, Valerie
    Tajimi, Masaomi
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 647 - 656
  • [37] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
  • [38] SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
    Gonzalez-Angulo, Ana M.
    Krop, Ian
    Akcakanat, Argun
    Chen, Huiqin
    Liu, Shuying
    Li, Yisheng
    Culotta, Kirk S.
    Tarco, Emily
    Piha-Paul, Sarina
    Moulder-Thompson, Stacy
    Velez-Bravo, Vivianne
    Sahin, Aysegul A.
    Doyle, Laurence A.
    Do, Kim-Anh
    Winer, Eric P.
    Mills, Gordon B.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (03):
  • [39] Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
    Fujisaka, Yasuhito
    Yamada, Yasuhide
    Yamamoto, Noboru
    Shimizu, Toshio
    Fujiwara, Yutaka
    Yamada, Kazuhiko
    Tamura, Tomohide
    Watanabe, Hiroyuki
    Sun, Yu-Nien
    Bass, Michael B.
    Seki, Mitsuo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) : 935 - 943
  • [40] Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
    Yasuhito Fujisaka
    Yasuhide Yamada
    Noboru Yamamoto
    Toshio Shimizu
    Yutaka Fujiwara
    Kazuhiko Yamada
    Tomohide Tamura
    Hiroyuki Watanabe
    Yu-Nien Sun
    Michael B. Bass
    Mitsuo Seki
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 935 - 943
12345